Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies
Abstract
Background: Some chronic hepatitis C virus (HCV), genotype 1 infected patients treated with direct antiviral agents (DAAs) remain viremic at end of treatment (EOT+), yet go on to achieve sustained virological response 12 weeks after completion of therapy (SVR12). The incidence of EOT+/SVR in patients with genotype 1 and other genotypes, as well as whether such patients achieve SVR24 remain in question. The aims of this study were to evaluate the frequency and durability of EOT+/SVR12&24 and other response categories in HCV genotype 1, 2, or 3 infected patients treated with DAA in clinical practice. Methods: Data from patients treated with all oral sofosbuvir-based regimens at a university hepatology practice by 1 July 2015 were reviewed retrospectively. Responses were categorized based on virus levels during and post DAA treatment. HCV RNA levels were measured by Abbott RealTime HCV (ART) or by Roche CobasTaqMan v2.0 (RCTM) assays. Results: The study population included 89 patients. Participants were 62% genotype 1, 19% genotype 2 and 19% genotype 3, 54% cirrhotic and 46% treatment-experienced. A total of 45 received sofosbuvir-simeprevir, 38 sofosbuvir-ribavirin and 6 sofosbuvir-ledipasvir. The SVR12 rate was 82%. A total of 5 patients (6%), all with genotype 1, had EOT+ by ARTmore »
- Authors:
-
- Univ. of Florida Health, Jacksonville, FL (United States)
- Loyola Univ. Medical Center, Maywood, IL (United States)
- Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
- Publication Date:
- Research Org.:
- Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
- Sponsoring Org.:
- USDOE; National Institutes of Health (NIH)
- OSTI Identifier:
- 1626246
- Grant/Contract Number:
- AC52-06NA25396; R01-AI078881; R01-OD011095; P20-GM10 3452
- Resource Type:
- Accepted Manuscript
- Journal Name:
- Therapeutic Advances in Gastroenterology
- Additional Journal Information:
- Journal Volume: 10; Journal Issue: 1; Journal ID: ISSN 1756-283X
- Publisher:
- SAGE
- Country of Publication:
- United States
- Language:
- English
- Subject:
- 60 APPLIED LIFE SCIENCES; Gastroenterology & Hepatology; HCV; SVR; direct antiviral agents; end of treatment response
Citation Formats
Malespin, Miguel, Benyashvili, Tamara, Uprichard, Susan L., Perelson, Alan S., Dahari, Harel, and Cotler, Scott J. Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies. United States: N. p., 2016.
Web. doi:10.1177/1756283x16672392.
Malespin, Miguel, Benyashvili, Tamara, Uprichard, Susan L., Perelson, Alan S., Dahari, Harel, & Cotler, Scott J. Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies. United States. https://doi.org/10.1177/1756283x16672392
Malespin, Miguel, Benyashvili, Tamara, Uprichard, Susan L., Perelson, Alan S., Dahari, Harel, and Cotler, Scott J. Sun .
"Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies". United States. https://doi.org/10.1177/1756283x16672392. https://www.osti.gov/servlets/purl/1626246.
@article{osti_1626246,
title = {Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies},
author = {Malespin, Miguel and Benyashvili, Tamara and Uprichard, Susan L. and Perelson, Alan S. and Dahari, Harel and Cotler, Scott J.},
abstractNote = {Background: Some chronic hepatitis C virus (HCV), genotype 1 infected patients treated with direct antiviral agents (DAAs) remain viremic at end of treatment (EOT+), yet go on to achieve sustained virological response 12 weeks after completion of therapy (SVR12). The incidence of EOT+/SVR in patients with genotype 1 and other genotypes, as well as whether such patients achieve SVR24 remain in question. The aims of this study were to evaluate the frequency and durability of EOT+/SVR12&24 and other response categories in HCV genotype 1, 2, or 3 infected patients treated with DAA in clinical practice. Methods: Data from patients treated with all oral sofosbuvir-based regimens at a university hepatology practice by 1 July 2015 were reviewed retrospectively. Responses were categorized based on virus levels during and post DAA treatment. HCV RNA levels were measured by Abbott RealTime HCV (ART) or by Roche CobasTaqMan v2.0 (RCTM) assays. Results: The study population included 89 patients. Participants were 62% genotype 1, 19% genotype 2 and 19% genotype 3, 54% cirrhotic and 46% treatment-experienced. A total of 45 received sofosbuvir-simeprevir, 38 sofosbuvir-ribavirin and 6 sofosbuvir-ledipasvir. The SVR12 rate was 82%. A total of 5 patients (6%), all with genotype 1, had EOT+ by ART assay and each achieved SVR12&24. Conclusions: A total of 9% of genotype 1 patients (6% overall) treated with DAAs were EOT+ by ART and all EOT+ cases achieved SVR24. EOT+/SVR was not observed with genotype 2 or 3 or by the RCTM assay. In patients treated with DAAs, EOT+ by the ART assay does not indicate treatment failure.},
doi = {10.1177/1756283x16672392},
journal = {Therapeutic Advances in Gastroenterology},
number = 1,
volume = 10,
place = {United States},
year = {Sun Oct 16 00:00:00 EDT 2016},
month = {Sun Oct 16 00:00:00 EDT 2016}
}
Web of Science
Works referenced in this record:
Sustained Virologic Response for Chronic Hepatitis C Infection After 27 Days of Treatment with Sofosbuvir and Ribavirin
journal, January 2014
- Meissner, Eric G.; Nelson, Amy; Marti, Miriam
- Open Forum Infectious Diseases, Vol. 1, Issue 1
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
journal, August 2014
- Jacobson, Ira M.; Dore, Gregory J.; Foster, Graham R.
- The Lancet, Vol. 384, Issue 9941, 403-413
Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials: Table 1.
journal, May 2015
- Harrington, Patrick R.; Deming, Damon J.; Komatsu, Takashi E.
- Clinical Infectious Diseases, Vol. 61, Issue 4
Performance of Two HCV RNA Assays during Protease Inhibitor-Based Triple Therapy in Patients with Advanced Liver Fibrosis and Cirrhosis
journal, November 2014
- Maasoumy, Benjamin; Hunyady, Bela; Calvaruso, Vincenza
- PLoS ONE, Vol. 9, Issue 11
Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens
journal, September 2016
- Maasoumy, Benjamin; Vermehren, Johannes; Welker, Martin-Walter
- Journal of Hepatology, Vol. 65, Issue 3
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
journal, March 2011
- Poordad, Fred; McCone, Jonathan; Bacon, Bruce R.
- New England Journal of Medicine, Vol. 364, Issue 13
Reply to Harrington et al
journal, May 2015
- Sidharthan, Sreetha; Kohli, Anita; Kottilil, Shyam
- Clinical Infectious Diseases, Vol. 61, Issue 4
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
journal, September 2002
- Fried, Michael W.; Shiffman, Mitchell L.; Reddy, K. Rajender
- New England Journal of Medicine, Vol. 347, Issue 13
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
journal, August 2014
- Jacobson, Ira M.; Dore, Gregory J.; Foster, Graham R.
- The Lancet, Vol. 384, Issue 9941
Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy
journal, March 2015
- Sarrazin, Christoph; Wedemeyer, Heiner; Cloherty, Gavin
- Journal of Virological Methods, Vol. 214
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study
journal, March 2015
- Kohli, Anita; Osinusi, Anuoluwapo; Sims, Zayani
- The Lancet, Vol. 385, Issue 9973
Utility of Hepatitis C Viral Load Monitoring on Direct-Acting Antiviral Therapy
journal, March 2015
- Sidharthan, Sreetha; Kohli, Anita; Sims, Zayani
- Clinical Infectious Diseases, Vol. 60, Issue 12
Sporadic Reappearance of Minute Amounts of Hepatitis C Virus RNA After Successful Therapy Stimulates Cellular Immune Responses
journal, February 2011
- Veerapu, Naga Suresh; Raghuraman, Sukanya; Liang, T. Jake
- Gastroenterology, Vol. 140, Issue 2
Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection
journal, May 2014
- Vermehren, Johannes; Aghemo, Alessio; Falconer, Karolin
- Journal of Hepatology, Vol. 60, Issue 5
Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients
journal, June 2014
- Zeuzem, Stefan; DeMasi, Ralph; Baldini, Alessandra
- Journal of Hepatology, Vol. 60, Issue 6
Difficult-to-cure populations with chronic hepatitis c: Vanishing in the direct-acting antiviral era?
journal, June 2015
- Terrault, Norah
- Hepatology, Vol. 62, Issue 1
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus
journal, November 2014
- Yoshida, Eric M.; Sulkowski, Mark S.; Gane, Edward J.
- Hepatology, Vol. 61, Issue 1
Peginterferon Alfa-2a and Ribavirin for 24 Weeks in Hepatitis C Type 1 and 4 Patients With Rapid Virological Response
journal, August 2008
- Ferenci, Peter; Laferl, Hermann; Scherzer, Thomas–Matthias
- Gastroenterology, Vol. 135, Issue 2
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
journal, September 2001
- Manns, Michael P.; McHutchison, John G.; Gordon, Stuart C.
- The Lancet, Vol. 358, Issue 9286
Boceprevir (Victrelis) for HCV: V is for victory and very complex
journal, October 2011
- Charlton, Michael; Leise, Michael D.
- Hepatology, Vol. 54, Issue 5
Research is needed on the difficult‐to‐cure population of hepatitis C virus patients with disability
journal, October 2015
- Chirikov, Viktor; Shaya, Fadia; Mullins, C. Daniel
- Hepatology, Vol. 63, Issue 6
Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection
journal, May 2014
- Vermehren, Johannes; Aghemo, Alessio; Falconer, Karolin
- Journal of Hepatology, Vol. 60, Issue 5
Resurrection of response-guided therapy for sofosbuvir combination therapies
journal, September 2016
- Dahari, Harel; Halfon, Phillippe; Cotler, Scott J.
- Journal of Hepatology, Vol. 65, Issue 3
Peginterferon alfa-2b plus ribavirin for chronic hepatitis
journal, January 2002
- Santin, Miguel; Shaw, Evelyn
- The Lancet, Vol. 359, Issue 9302
Peginterferon Alfa-2a and Ribavirin for 24 Weeks in Hepatitis C Type 1 and 4 Patients With Rapid Virological Response
journal, August 2008
- Ferenci, Peter; Laferl, Hermann; Scherzer, Thomas–Matthias
- Gastroenterology, Vol. 135, Issue 2
Sporadic Reappearance of Minute Amounts of Hepatitis C Virus RNA After Successful Therapy Stimulates Cellular Immune Responses
journal, February 2011
- Veerapu, Naga Suresh; Raghuraman, Sukanya; Liang, T. Jake
- Gastroenterology, Vol. 140, Issue 2
Utility of Hepatitis C Viral Load Monitoring on Direct-Acting Antiviral Therapy
journal, March 2015
- Sidharthan, Sreetha; Kohli, Anita; Sims, Zayani
- Clinical Infectious Diseases, Vol. 60, Issue 12
Reply to Harrington et al
journal, May 2015
- Sidharthan, Sreetha; Kohli, Anita; Kottilil, Shyam
- Clinical Infectious Diseases, Vol. 61, Issue 4
Performance of Two HCV RNA Assays during Protease Inhibitor-Based Triple Therapy in Patients with Advanced Liver Fibrosis and Cirrhosis
journal, November 2014
- Maasoumy, Benjamin; Hunyady, Bela; Calvaruso, Vincenza
- PLoS ONE, Vol. 9, Issue 11
HCV RNA quantification with different assays: implications for protease inhibitor-based response-guided therapy
journal, January 2014
- Fevery, Bart; Susser, Simone; Lenz, Oliver
- Antiviral Therapy, Vol. 19, Issue 6
Works referencing / citing this record:
Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis
journal, December 2018
- Gambato, Martina; Canini, Laetitia; Lens, Sabela
- Liver International, Vol. 39, Issue 5
Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era
journal, August 2018
- Raja, Rubesh; Baral, Subhasish; Dixit, Narendra M.
- Immunological Reviews, Vol. 285, Issue 1
Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection
journal, July 2018
- Venugopal, Vishnu; Padmanabhan, Pranesh; Raja, Rubesh
- PLOS Computational Biology, Vol. 14, Issue 7
Significance of detectable HCV RNA below the limit of quantification in patients treated with DAAs using standard and ultrasensitive protocols
journal, April 2018
- Visco-Comandini, Ubaldo; Lapa, Daniele; Lionetti, Raffaella
- Journal of Medical Virology, Vol. 90, Issue 7
Towards multiscale modeling of the CD8
+
T cell response to viral infections
journal, February 2019
- Baral, Subhasish; Raja, Rubesh; Sen, Pramita
- WIREs Systems Biology and Medicine, Vol. 11, Issue 4
Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection
journal, July 2018
- Venugopal, Vishnu; Padmanabhan, Pranesh; Raja, Rubesh
- PLOS Computational Biology, Vol. 14, Issue 7